HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

VABOMERE Shows Higher Cure Rate in Patients with CRE Infections Vs. Best Available Therapy

Michael N. Dudley, PharmD, explains how VABOMERE was associated with a higher overall cure rate and lower mortality compared with the best available therapy in patients with CRE infections in a recent trial.

Michael N. Dudley, PharmD, senior vice president and head of R&D at the Medicines Company, discusses the results of the TANGO II study of VABOMERE, a new beta-lactam that combines meropenem and vaborbactam. In patients with carbapenem-resistant Enterobacteriaceae (CRE), VABOMERE was associated with a higher overall cure and lower mortality compared with the best available therapy.

Related Content:

ID WeekVideosANTIBIOTICSConferences
10 Years After HIV PrEP Approval, Uptake Lowest Among Highest Risk Groups
In Low-Income Communities, Pharmacists Can Play a Critical Role in Vaccine Access
Infectious Disease Virologist: “Nobody Should be Scared of Paxlovid Rebound”